Results 251 to 260 of about 767,969 (287)

ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis

Biochemical and Biophysical Research Communications, 2021
Juntao Li, zhenduo Lu, Zhengzhi Zou
exaly  

Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours

European Journal of Cancer, 2023
Patrick Schöffski, Jean-Pascal Machiels, Ahmad Awada   +2 more
exaly  

Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells

Genomics, 2021
Bing Xiong, Ze-Hong Miao, Peng Wang
exaly  

Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors

Pharmacology & Therapeutics, 2020
Patrick Schöffski, Oliver Bechter
exaly  

XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America, 2022
Thao N D Pham, Kiira Ratia, Rui Xiong
exaly  

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor

Molecular Therapy - Oncolytics, 2021
Satyanarayana Alleboina, Kevin W Freeman, Nour Aljouda   +2 more
exaly  

Tricyclic heterocycles as BET protein inhibitors

2015
YUE EDDY W, COMBS ANDREW P, BUESKING ANDREW W   +2 more
openaire   +10 more sources

DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4

Molecular Cell, 2018
Xin Jin, Heshui Wu, Liguo Wang
exaly  

A BET inhibitor workaround

Nature Chemical Biology, 2016
openaire   +1 more source

Investment in Cancer Control and Research: A Sure Bet†

Ca-A Cancer Journal for Clinicians, 2006
Carolyn D Runowicz
exaly